New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 29, 2014
06:07 EDTFOLDAmicus Therapeutics announces positive results from Pahse 3 Fabry study
Amicus Therapeutics announced positive 12- and 24-month data from its first Phase 3 study of the oral small molecule chaperone migalastat HCl monotherapy in Fabry patients with amenable mutations. Study 011 was designed to measure the reduction of disease substrate following treatment with migalastat. The 24-month study began with a 6-month double-blind, placebo-controlled treatment period, after which all patients were treated with migalastat for a 6-month open-label follow-up period and a subsequent 12-month open-label extension phase. As previously reported, patients on migalastat experienced greater reductions in GL-3 as compared to placebo during the initial 6-month period; however, this difference was not statistically significant under the original study primary endpoin
News For FOLD From The Last 14 Days
Check below for free stories on FOLD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
11:08 EDTFOLDHigh option volume stocks
Subscribe for More Information
11:06 EDTFOLDSummer Street chief scientific officer holds an analyst/industry conference call
Chief Scientific Officer Classen discusses Amicus Therapeutics' Migalastat for Fabry's disease on an Analyst/Industry conference call to be held on July 23 at 2 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use